Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Wnt/β-catenin–activated Ewing sarcoma cells promote the angiogenic switch
Allegra G. Hawkins, Elisabeth A. Pedersen, Sydney Treichel, Kelsey Temprine, Colin Sperring, Jay A. Read, Brian Magnuson, Rashmi Chugh, Elizabeth R. Lawlor
Allegra G. Hawkins, Elisabeth A. Pedersen, Sydney Treichel, Kelsey Temprine, Colin Sperring, Jay A. Read, Brian Magnuson, Rashmi Chugh, Elizabeth R. Lawlor
View: Text | PDF
Research Article Cell biology Oncology

Wnt/β-catenin–activated Ewing sarcoma cells promote the angiogenic switch

  • Text
  • PDF
Abstract

Wnt/β-catenin signaling is active in small subpopulations of Ewing sarcoma cells, and these cells display a more metastatic phenotype, in part due to antagonism of EWS-FLI1–dependent transcriptional activity. Importantly, these β-catenin–activated Ewing sarcoma cells also alter secretion of extracellular matrix (ECM) proteins. We thus hypothesized that, in addition to cell-autonomous mechanisms, Wnt/β-catenin–active tumor cells might contribute to disease progression by altering the tumor microenvironment (TME). Analysis of transcriptomic data from primary patient biopsies and from β-catenin–active versus –nonactive tumor cells identified angiogenic switch genes as being highly and reproducibly upregulated in the context of β-catenin activation. In addition, in silico and in vitro analyses, along with chorioallantoic membrane assays, demonstrated that β-catenin–activated Ewing cells secreted factors that promote angiogenesis. In particular, activation of canonical Wnt signaling leads Ewing sarcoma cells to upregulate expression and secretion of proangiogenic ECM proteins, collectively termed the angiomatrix. Significantly, our data show that induction of the angiomatrix by Wnt-responsive tumor cells is indirect and is mediated by TGF-β. Mechanistically, Wnt/β-catenin signaling antagonizes EWS-FLI1–dependent repression of TGF-β receptor type 2, thereby sensitizing tumor cells to TGF-β ligands. Together, these findings suggest that Wnt/β-catenin–active tumor cells can contribute to Ewing sarcoma progression by promoting angiogenesis in the local TME.

Authors

Allegra G. Hawkins, Elisabeth A. Pedersen, Sydney Treichel, Kelsey Temprine, Colin Sperring, Jay A. Read, Brian Magnuson, Rashmi Chugh, Elizabeth R. Lawlor

×

Figure 2

Wnt-activated Ewing sarcoma cells induce the angiogenic switch gene signature.

Options: View larger image (or click on image) Download as PowerPoint
Wnt-activated Ewing sarcoma cells induce the angiogenic switch gene sign...
(A) Unbiased GSEA of LEF1-correlated genes in 2 independent tumor cohorts as in Figure 1. All expressed transcripts were ranked on the basis of LEF1 correlations, from positive to negative. For GSEA, 2-sided t tests were performed followed by multiple test comparison using FDR. Only gene sets with FDR < 0.05 are displayed. (B) Heatmap demonstrating relative expression of differentially expressed angiogenic switch genes in β-catenin/TCF–active cells compared with β-catenin/TCF–inactive cells. Data from ref. 11 (GSE75859) wherein CHLA25 Ewing sarcoma cells were treated with control or Wnt3a CM ± R-spondin 2 and β-catenin/TCF–active and –nonactive cells were isolated by FACS on the basis of TCF-GFP reporter activity. Data are expressed as fold change in expression in GFP+ tumor cells compared with GFP– control cells. (C) Corresponding official gene ID for ensembl transcripts represented in heatmap in B. P value for overlap between Wnt pathway–regulated genes and angiogenic switch genes was computed using χ2 test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts